Melanie Kelly

Melanie Kelly

Company: Tetra Biopharma

Job title: Chief Scientific Officer


Development of Novel Injectable and Inhaled Cannabinoid Drugs for Systemic Inflammation and ARDS 9:00 am

• Evidence supporting the Cannabinoid Type 2 receptor (CB2) as an important immunemodulatory target • Challenges, successes and caveats in the development and positioning of Cannabinoid Therapeutics for Systemic Inflammation • Bridging the gap between systemic and inhaled cannabinoids for ARDSRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.